Plasma phospholipids and platelet function in uremic patients.
An increased activity of phospholipase A2 has been observed in the plasma of patients with uremia. This enzyme converts phosphatidylcholine to lysophosphatidylcholine (LPC), an inhibitor of platelet aggregation. We measured the levels of plasma phospholipids including LPC, and platelet aggregation in 7 patients with uremia. Platelet response to agonists was defective, mainly with collagen (p < 0.001). The patients' levels of LPC in plasma were similar to those of controls (109.7 +/- 41.6 vs. 80.4 +/- 16.8 nmol/ml) and did not correlate with the platelet response to adenosine diphosphate (r = -0.51). The amount of phosphatidylcholine was increased with respect to normal plasma (1,041.0 +/- 201.8 vs. 760.8 +/- 142.7 nmol/ml, p < 0.01), while the levels of other phospholipids were normal. These results do not suggest a participation of plasma LPC in the genesis of the platelet defect observed in patients with uremia.
Vecino
A
A
Department of Hematology, Hospital Ramón y Cajal, Madrid, Spain.
Teruel
J L
JL
Navarro
J L
JL
Cesar
J M
JM
D000293:Adolescent; D000328:Adult; D001760:Bleeding Time; D001792:Blood Platelets / Q000502:physiology*; D002855:Chromatography, Thin Layer; D005260:Female; D006801:Humans; D008244:Lysophosphatidylcholines / Q000097:blood; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000097:blood*; D010974:Platelet Aggregation / Q000502:physiology*; D014511:Uremia / Q000097:blood*
D008244:Lysophosphatidylcholines; D010743:Phospholipids